Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:30:47 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Albert Labs International Corp
Symbol ABRT
Shares Issued 74,413,267
Close 2023-08-31 C$ 0.025
Market Cap C$ 1,860,332
Recent Sedar+ Documents

Albert Labs directors Raymont, Thompson resign

2023-09-05 12:12 ET - News Release

Subject: Albert Labs - News Release PDF Document File: Attachment AL. PR - September 5, 2023 BOD and Management Announcment.pdf Albert Labs Management and Board of Director Announcement September 5th, 2023 - VANCOUVER, BRITISH COLUMBIA, Albert Labs International Corp. (Albert Labs (CSE: ABRT) (FSE: VB50), the "Company") announces, effective immediately, that Michael Raymont has resigned from his position of Chief Executive Officer and Director of the Company and Mike Thompson has resigned from the Board of Directors. The Board of Directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the Company. Mr Chand Jagpal will be acting as the Interim Chief Executive Officer until a suitable candidate is found. Business of Albert Labs International Corp. Albert Labs is a pharmaceutical drug development company, focussed on gaining regulatory approval for active compounds in the treatment of mental health, and providing rapid access to effective prescription medicines for people suffering from mental health disorders. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which the needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognised clinical route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines. Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs' first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide. The company's goal is to deliver effective medicines to suffers with mental health concerns in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders. Albert Labs (CSE: ABRT) (FSE: VB50) is publicly listed on the Canadian Securities Exchange (CSE). You can find more details about Albert Labs on our website here. ON BEHALF OF THE BOARD OF DIRECTORS Albert Labs International Corp. Chand Jagpal Chief Financial Officer For further information please contact: Email: press@albertlabs.com Website: https://albertlabs.com/ Tel: +1 778-819-0740 Tel: +44 1625 324 960 Cautionary Statement This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward- looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate. The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements. Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward- looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws. 2

© 2026 Canjex Publishing Ltd. All rights reserved.